GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +022 2495 9595
Fax No: +022 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

February 5, 2020

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Presentation for Analyst Meet

Pursuant to regulation 30 of SEBI (Listing obligations and Disclosure Requirement), 2015 we are enclosing the presentation given in the Analyst / Institutional Investor Meeting held on 4th February 2020.

The details of the presentation are also available at the Company's website www.GSK-india.com .

Thanking you,

Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited

for Ajay Nadkarni
Vice President – Admin, Real Estate
& Company Secretary

Encl:

Analysts' Meet

4 February 2020

Agenda


Financial Performance YTD / Q3 2019-20
Vemgal Update
Unexpected Development: Ranitidine
India Growth Story
Innovation Focus

Performance YTD / Q3 19-20

YTD EBIDTA margin +1%; YTD EPS +11%; GP margin +3%

Performance YTD

Headline Growth 3%; Underlying 13% (7% Volume + 6% Price)



Portfolio	Value	Growth
Key Brands	1479Cr	+21%
Rx Key Brands	*963Cr*	*+18%*
Vx Key Brands	*516Cr*	*+26%*

Performance Q3

Q3 Sales

Sales	770 Cr / -6%
Underlying growth	+6%

Portfolio	Value	Growth
Key Brands	479Cr	+12%
Rx Key Brands	*304Cr*	*+8%*
Vx Key Brands	*176Cr*	*+20%*

External Growth

- 2x the market for Promoted brands with EI at 106
- Underlying external growth is 12% with EI of 102

YTD 2019-20 – Performance v PY YTD

Headline: Sales +3% , PAT before exceptional +11%
Exceptional Charge 336 Cr from impairment and related costs



Q3 2019-20 – Performance v PY

Headline: Sales - 6% , PAT (before exceptional) @ 9%

Exceptional Charge 737 Cr from impairment and related costs



Agenda


Financial Performance YTD / Q3 2019-20
Vemgal Update
Unexpected Development: Ranitidine
India Growth Story
Innovation Focus

Background of Vemgal

Situation

- ❑ Nashik – multi dose form facility; severely under invested. Need for remediation to maintain the Global GSK standards
- ❑ Need to increase capacity to cope up with strong business growth ambition ; maintain market share and maintain commitment to patient safety

Response / Objective

Planned robust futuristic supply chain for India -

- ❑ Seamless supply & business continuity to support strong business growth ambition; reduce reliance on Nashik
- ❑ Compliance to GSK Global standards and maintain commitment to patient safety

Proposal for a high volume Greenfield site for OSD (Oral Solid Dose)

Investment

- ❑ Greenfield project with 9bn dose capacity with INR 1000 cr investment – 60% capacity dedicated for Zinetac
- ❑ Focus on high volume low complexity products
- ❑ 2013: Initial project approval
- ❑ 2014: Vemgal project initiation
- ❑ 2019: Manufacturing license received with commercialization planned in 2019-20
- ❑ Sep 2019: Voluntary global recall of ranitidine products, including Zinetac in India.

Agenda


Financial Performance YTD / Q3 2019-20
Vemgal Update
Unexpected Development: Ranitidine
India Growth Story
Innovation Focus

Unexpected Global Development: Ranitidine

- NDMA (N-nitrosodimethylamine) issue highlighted in mid Sept 2019 leading to voluntary recall of Zinetac

- GSK continues to respond to queries from global regulatory authorities
  - The EMA has initiated an investigation into the potential root causes for the formation of NDMA in Ranitidine containing products

- The investigation into the causes for the formation of NDMA is highly complex
  - Root cause analysis is on-going & multiple options are being explored
  - Currently testing a significant representation of batches of finished product (tablets, effervescent tablets, IV solution, and syrup dose forms)
  - 20 scientists working full time have analysed over 360 batches to date

- Patient safety remains a top priority and it is fundamental to maintaining trust

Financial Evaluation

Options explored

- ❑ Alternate SKU production at site; Additional capital investment required hence low financial viability;
- ❑ Low volumes for alternate products leading to significant under utilization of capacity at Vemgal

Financial Governance

- ❑Ranitidine issue resulted in under-utilization and triggered an impairment
- ❑Recognize financial impairment of INR 640 cr connected to the underutilization of GSK's manufacturing facilities and INR 97 cr on account of other related assets / cost.

Agenda


Financial Performance YTD / Q3 2019-20
Vemgal Update
Unexpected Development: Ranitidine
India Growth Story
Innovation Focus

2019-2021: Accelerating India Rx profitable growth

Winning in right TAs

- Increased SoV on key brands to drive growth in AI, Derma and Vaccines
- Redeployment of 400 FTEs and increment of 200 FTE. Increase reach by 140K new HCPs
- Strengthen specialty pipeline with launch of Nucala and Menveo. Initiate registration process for Shingrix

Winning in channels

- Build trust with channels
- Acquire/ Build capability to engage with channels
- Build technology platforms to commercially transact with 100K pharmacies
- +100 FTE
- Order fulfilment of distributed brands (Non-promoted)

Winning with HCPs virtually

- Established a model for digital only promotion for 6 identified brands with agency onboard
- Enhance customer experience through increased touchpoint (1.5x) enabled by MCM
- Focus to drive higher Qualified Reach

Improved supply efficiency with focus on OTIF/ Inventory

Agenda


Financial Performance YTD / Q3 2019-20
Vemgal Update
Unexpected Development: Ranitidine
India Growth Story
Innovation Focus

Innovation Focus

Innovation

- Continued success of Nucala (Mepolizumab) which is a humanised monoclonal antibody and indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients
- Launch of Menveo vaccine for protection against meningococcal disease.
- Continued commitment on introducing new therapies / specialities in the market both in Pharma and Vaccines with the initial success of Nucala and Menveo.



MENVEO
Meningococcal Group A,C,W135 & Y
Conjugate Vaccine Ph. Eur.